Targeting Mitochondrial Dysfunction

Our lead product, Imeglimin, is in Phase 3 development in Japan and has successfully completed Phase 2 development in the U.S. and EU.

View Candidate
Targeting Mitochondrial Dysfunction

Innovative Pipeline of First-In-Class Products

Our candidates are based on disease-modifying mechanisms of action that offer the potential for safer and more effective therapies for type 2 diabetes and NASH.

View Pipeline
Innovative Pipeline of First-In-Class Products

Backed by Strong Leadership

Our highly-experienced clinical and regulatory teams possess the know-how and experience to successfully develop products within our pipeline.

Meet Our Team
Backed by Strong Leadership

Latest News

Poxel Reports Financial Update for Cash and Revenue for the Full Year 2019 and Provides Corporate Update

LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and…

Read this Press Release: Poxel Reports Financial Update for Cash and Revenue for the Full Year 2019 and Provides Corporate Update

Poxel Presents New Preclinical Proof-of-Concept Results for PXL770 at the 3rd Annual Global NASH Congress

PXL770, a novel direct AMP kinase activator, observed to reduce liver inflammatory cells, which may contribute to an improvement of fibrogenesis, in a preclinical NASH model Clinical results from the PXL770 PK/PD…

Read this Press Release: Poxel Presents New Preclinical Proof-of-Concept Results for PXL770 at the 3rd Annual Global NASH Congress

Poxel Appoints Industry Leader Dr. David E. Moller as Chief Scientific Officer

LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and…

Read this Press Release: Poxel Appoints Industry Leader Dr. David E. Moller as Chief Scientific Officer
Click here to show the previous slide Click here to show the next slide